Dapagliflozin Tested in Adults With Long COVID Syndrome
Tests dapagliflozin against a placebo in adults with long COVID syndrome.
Plain-language title generated from the registry record
Registry title: Dapagliflozin for Long COVID Syndrome
Key facts
- Where
- Ottawa, CanadaSee the site
- Phase
- Phase 3
Where in Canada
- University of Ottawa Heart InstituteOttawa, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ottawa Heart Institute Research Corporation
- Trial code
- NCT06907251
- Record updated
- 30 October 2026
- Original description
This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.Read full original descriptionShow less
Dapagliflozin for Long COVID Syndrome
This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.
Inclusion: 18 years of age or older and willing and able to provide informed consent; Patients with a history of positive COVID-19 test (polymerase chain reaction or rapid test) or have been diagnosed with COVID-19 by a health care provider; New or persistent symptoms at least 12 weeks from infection and present for at least 8 weeks that is not explained by an alternative diagnosis (64); Women of childbearing potential (WOCBP) who, if sexually active, are willing to use to use at least one highly effective methods of contraception throughout the study.
Exclusion: Prior heart failure; Weight loss treatment with glucagon-like peptide-1 receptor agonists (e.g. liraglutide, semaglutide); History of diabetes; Known history of allergy or hypersensitivity to dapagliflozin; Exclusion for optional MRI portion of the protocol:; Severe renal impairment (eGFR<30mL/min1.73m2); Pregnancy or planned pregnancy in the next 12 months. We will ask WOCBP about the possibility of pregnancy at the time of screening and if so, then pregnancy testing will be offered. If testing is declined in this instance, then they will be excluded from the study; Women who are breastfeeding; Any contraindication to MRI.